Recent Transactions

Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO

Advising Eisai, a Japanese pharmaceutical company, on the sale of Eisai Distribution, a 100% shares holding logistic subsidiary, to Yasuda Logistics Corporation, a Japanese logistic company conducting total logistic services such as Warehousing, Transportation, delivery and forwarding, and Port transportation business, etc.

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company

Advising brsk, a UK-based alternative network broadband provider, on its first debt-raise of £178m from Ares Management, a leading global alternative investment manager

Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners

Advising Mitsui Chemicals,  one of the largest Japanese chemical companies, on the acquisition of a 30% stake in Japan Medical Dynamic Marketing, a leading orthopedic medical device manufacturer in Japan, held by NGK SPARK PLUG

Advised Antin Infrastructure Partners on its acquisition of Pulsant from Oak Hill and Scottish Equity Partners. Pulsant is a hybrid cloud specialist, with a nationwide network of 10 data centres across the UK delivering secure, scalable and resilient cloud, colocation and networking services

Advised Siris Capital, a private equity firm focused on the technology sector, on its recommended 180p cash offer for Equiniti Group PLC, a technology-led services and payments specialist

Advised Fluor Corporation, a global engineering, procurement and construction company and the majority investor in NuScale, a leading developer of small modular reactor nuclear technology, on the equity capital raise for NuScale

Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc

Advised Castleton Resources, a Houston, TX based, privately held oil and gas operator, on its acquisition of Range Resources’ Terryville Assets. As part of the transaction, Castleton Resources will change its name to “TG Natural Resources LLC” by late March 2021. Range Resources (NYSE: RRC) is a Fort Worth, TX based E&P company with primary operations in the Marcellus Shale formation.

Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia,  the largest health insurance provider in the Kingdom of Saudi Arabia

Advised Eppendorf AG, a leading family-owned life science company, on the acquisition of the centrifuge and processing equipment business of KKR-owned Koki Holdings Co., Ltd., a manufacturer of power tools and centrifuge and processing equipment 

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd

Advised CME Group, Inc., the operator of a leading global derivatives marketplace, on the structured sale of its 25% equity stake in Bursa Malaysia Derivatives Berhad to Bursa Malaysia Berhad

Advised Renewi plc, a leading waste to product company, on the sale of its Canadian operations to Convent Capital, an Amsterdam-based investment firm

Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture

Advised TAL, Australia’s largest and leading insurance business that is 100% owned by Dai-ichi Life of Japan, on the acquisition of Suncorp Group Limited’s Australian Life Insurance business

Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt

Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture

Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab

Advised Equiniti Group plc, a UK based specialist technology outsourcer providing non-discretionary payment and administration services, on the acquisition of Wells Fargo's Shareowner Services business, and acted as joint sponsor to Equiniti's associated £122 million rights issue

Advised LCH.Clearnet Group Limited, a leading multi-asset class European clearing house, on a sale of LCH.Clearnet SA, its French-regulated operating subsidiary, to Euronext N.V. that was ultimately terminated

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila

Advised 3i Infrastructure plc, a leading UK listed investor in infrastructure businesses and assets, on its acquisition of a 36% economic interest in Wireless Infrastructure Group, the UK’s 2nd largest independent telecommunications tower company

Advised Fluor Corporation on its $489 million investment for a 49% interest in a joint venture with Offshore Oil Engineering Co., Ltd. (COOEC) to own, operate and manage the Zhuhai Fabrication Yard in China’s Guangdong province

Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc

Advised NYK Ports LLC, a leading port operating and stevedoring company, on the sale of a 49% stake to Macquarie Infrastructure Partners, a leading Australian infrastructure fund

Advised the Independent Committee of the Board of Essar Energy plc in connection with possible offers from Essar Global Fund Limited, its 78% shareholder, for the remaining shares it does not already own and $550mm convertible bonds issued by Essar Energy plc

Advised on the comprehensive restructuring of its balance sheet, including sale of the US business, terming out the existing RCF and creation of additional liquidity by the long term deferral of business partner payments

Advised Det Norske Veritas on its merger with Germanischer Lloyd to create the third largest player in the Testing, Inspection and Certification industry, focused on ship classification, oil & gas and energy

Advised the Special Committee of the Conflicts Committee of the Board of Directors of Athene Holding Ltd. in connection with the purchase of non-cash investment assets of AP Alternative Assets L.P.

Advised Virgin Money, a financial services provider, on the acquisition of Northern Rock, a UK retail mortgage and savings bank, from UK Financial Investments Ltd, which manages the UK Government’s investments in financial institutions

Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion

Advised Close Brothers plc, an independent financial services group, on the sale of its Cayman based offshore business to Intertrust Group Holdings SA

Advised TOWER Australia Group Limited, the largest mono-line life insurance company in Australia, in relation to the offer from The Dai-ichi Life Insurance Company, Limited to acquire all of the shares in TOWER that it does not already own by way of a scheme of arrangement

Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK

Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company

Advised GPG plc, a listed investment company, on potential restructuring alternatives

Advised United Kingdom Atomic Energy Authority Non Departmental Public Body, arm of the UK Government, on the sale of UKAEA Limited, its commercial nuclear decommissioning services business, to Babcock International Group plc

Advised Close Brothers Group plc, an independent financial services group, on the sale of its corporate finance subsidiary to Daiwa Securities SMBC Europe Ltd.

Advised NewSmith Capital, an independent investment management group, on a strategic agreement with UniCredit whereby UniCredit will acquire NewSmith’s Financial Products credit advisory business, assume a 5% stake in NewSmith Capital and become an investor in NewSmith funds

Advised Nikko Cordial, one of Japan’s largest securities firms, on its share exchange with Citigroup Inc., which resulted in Citigroup’s acquisition of the remaining 32% of Nikko Cordial that it did not already own

(25.1% stake)
Advised The Nasdaq Stock Market, Inc., the largest electronic equity securities market in the United States, on the acquisition of a 25.1% stake in London Stock Exchange plc

Advised bondholders of Drax Group Limited on the refinancing & listing of, and possible offers for, the company. On 15-Dec-05, Drax Group plc was successfully listed on the London Stock Exchange

held by Royal & Sun Alliance
Advised Royal & Sun Alliance on the sale of its 21.5% shareholding in Rothschilds Continuation Holdings AG to Jardine Strategic Holdings

46% stake in Waste Recycling Group plc
Advised Kelda Group plc on the disposal of its 46% stake in Waste Recycling Group plc.

Advised THUS plc on its underwritten £275 million open offer, £90 million bank loan and demerger from its parent, ScottishPower

Advised Kelda Group (formerly Yorkshire Water) on the all-cash purchase of Aquarion Company, a US water utility group.